Fig. 2: Cisplatin-induced autophagy confers decreased cisplatin cytotoxicity. | Cell Death & Disease

Fig. 2: Cisplatin-induced autophagy confers decreased cisplatin cytotoxicity.

From: BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism

Fig. 2

A, B Western blot analysis of BCAT1, p62, and LC3-I/II protein levels in the Hela (A) and HepG2 (B) cells treated with cisplatin (20 μM and 10 μM, respectively) alone or in combination with 20 μM chloroquine (CQ) for 24 h. C, D Western blot analysis of BCAT1, p62, and LC3-I/II protein levels in the Hela (C) and HepG2 (D) cells treated with cisplatin (20 μM and 10 μM, respectively) alone or in combination with 2 mM 3-methyladenine (3-MA) for 24 h. E, F Cell viability was assessed by CCK-8 assays. Hela (E) and HepG2 (F) cells were incubated with increasing concentrations of cisplatin alone or in combination with CQ (20 μM) for 24 h. G, H Cell viability was assessed by CCK-8 assays. Hela (G) and HepG2 (H) cells were incubated with increasing concentrations of cisplatin alone or in combination with 3-MA (2 mM) for 24 h. Three independent experiments were performed. ns, not significant. *P < 0.05, **P < 0.01.

Back to article page